U.S. markets closed

QuidelOrtho Corporation (QDEL)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
38.26-0.45 (-1.16%)
Al cierre: 04:00PM EDT
38.26 0.00 (0.00%)
Fuera de horario: 07:10PM EDT

QuidelOrtho Corporation

9975 Summers Ridge Road
San Diego, CA 92121
United States
858 552 1100
https://www.quidelortho.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo7,100

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael S. IskraInterim CEO, Executive VP & Chief Commercial Officer870.93kN/D1970
Mr. Robert J. Bujarski J.D.Interim President, Executive VP & COO961.26kN/D1969
Mr. Joseph M. Busky CPAChief Financial Officer890.63kN/D1968
Dr. Werner Kroll Ph.D.Senior Vice President of Research & Development1.03MN/D1957
Ms. Louise M. BrandyChief Information OfficerN/DN/D1959
Ruben ArguetaDirector of Investor RelationsN/DN/DN/D
Ms. Michelle A. Hodges J.D.Senior VP, General Counsel & Corporate Secretary1.8MN/D1963
Mr. William J. FerenczyPoint of Care Business Unit LeaderN/DN/D1956
Ms. Tamara A. RanalliMolecular Diagnostics Business Unit LeaderN/DN/D1973
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de QuidelOrtho Corporation a partir del 1 de abril de 2024 es 3. Las puntuaciones principales son Auditoría: 6; Junta: 2; Derechos del accionista: 4; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.